{"schema_version":"1.0","type":"article","title":"肌肉萎縮新藥在美獲准，每四週輸注如何走進生活？","url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.md","lang":"zh-Hant","date":"2026-09-26","publish_at":"2026-09-26T08:00:00+08:00","updated_at":"2026-09-26","category":"商業分析系列","topic":"商業分析系列","tags":["脊髓性肌肉萎縮症","Scholar Rock","ISEMBYLD","肌肉療法","安基生技"],"summary":"ISEMBYLD在美獲准，為接受SMN2治療的脊髓性肌肉萎縮症患者增加肌肉端療法。從一年功能增益、適用人群與安全追蹤，分析支付、每四週輸注及持續治療的商業考驗，並以安基AJ201說明台灣相鄰神經肌肉新藥開發能力與界線。","key_points":[],"facts":[],"sections":["【01｜從肌肉切入，建立既有治療之外的增量價值】","【02｜2.2 分如何產生，也決定療效故事怎麼說】","【03｜適用人群與安全性，決定長期價值的邊界】","【04｜約 6,600 人是公司估計的患者範圍，開始治療還有下一步】","【05｜每四週一次輸注，讓持續用藥成為另一個經營考驗】","【06｜台灣看的是開發能力：從候選藥走向人體驗證】","【結語｜從試驗增益走到日常治療，才是上市後的價值實現】","【資料來源】"],"references":[],"images":[{"alt":"抗體與骨骼肌、功能評估、患者及照護者接受輸注的三個場景，以問號連結；下方列美國核准日期及兩歲以上且接受SMN2治療的條件。","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care/01_%E6%96%B0%E5%A2%9E%E7%99%82%E6%B3%95%E8%88%87%E6%97%A5%E5%B8%B8%E4%BD%BF%E7%94%A8_ZH_v1.png"},{"alt":"運動神經元末端與骨骼肌相接，平行標示SMN2背景治療和新增ISEMBYLD；下方抗體抑制myostatin活化箭頭，未畫神經再生。","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care/02_%E7%A5%9E%E7%B6%93%E5%85%83%E8%88%87%E8%82%8C%E8%82%89_ZH_v1.png"},{"alt":"共同線性負2至正2刻度的兩柱：ISEMBYLD組從零至正1.0，安慰劑組從零至負1.2；括線跨兩端標示組間差2.2，附劑量、分母與研究人群。","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care/03_%E5%85%A9%E7%B5%84%E5%8A%9F%E8%83%BD%E5%B7%AE%E7%95%B0_ZH_v2.png"},{"alt":"患者與照護者連結功能評估、骨折等安全追蹤、支付與輸注安排三區；下方每四週靜脈輸注及由醫療團隊評估是否持續的限定。","url":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care/04_%E6%8C%81%E7%BA%8C%E6%B2%BB%E7%99%82%E4%B8%89%E9%9D%A2%E5%90%91_ZH_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/scholar-rock-isembyld-sma-care/01_%E6%96%B0%E5%A2%9E%E7%99%82%E6%B3%95%E8%88%87%E6%97%A5%E5%B8%B8%E4%BD%BF%E7%94%A8_ZH_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-26）。肌肉萎縮新藥在美獲准，每四週輸注如何走進生活？。https://drugnews.com.tw/articles/2026-09-26-scholar-rock-isembyld-sma-care.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-26-scholar-rock-isembyld-sma-care-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}